Breye Therapeutics completes phase 1B trial of danegaptide oral therapy for diabetic retinopathy

News
Article

Investigators reported the oral therapy was well-tolerated in trials for early treatment of non-proliferative diabetic retinopathy and associated oedema

A man in a bed takes a pill. Concept image for oral therapy, danegaptide non proliferative diabetic retinopathy medication. Image credit: ©Jelena – stock.adobe.com

The Phase 1b trial enrolled 24 patients across the United Kingdom, Germany and the US. Image credit: ©Jelena – stock.adobe.com

Breye Therapeutics announced the successful completion of its phase 1b clinical trial of an oral therapy (danegaptide) for early treatment of non-proliferative diabetic retinopathy (NPDR) and associated oedema.

Danegaptide is a first-in-class oral small molecule with a novel mode of action that stabilises the vasculature and protects against cell-cell uncoupling, retinal capillary breakdown and vascular leakage caused by hyperglycaemia, according to the company.

The drug has the potential to fill a treatment gap for these patients. While successful intravitreally administered products have been developed for patients with late-stage disease, treatment options are currently limited for patients in the earlier or moderate stages. The intravitreal treatments are burdensome, often poorly tolerated and associated with low compliance, highlighting the critical need for effective and non-invasive alternatives, according to the press release.

Phase 1 trial

The Phase 1b trial was a multicentre, open-label, dose-escalation study that assessed the safety, tolerability, pharmacokinetics and early signs of biologic activity of danegaptide in patients with NPDR and associated diabetic macular edema. The study, which enrolled 24 patients, was performed in 11 clinical sites in the United Kingdom, Germany and the US.

According to a press release from the company, the first-in-class oral treatment demonstrated that

  • The oral treatment was well tolerated, with early signs of clinical activity
  • In models of NPDR, danegaptide has demonstrated protection against retinal capillary loss and vascular leakage
  • Data support continued advancement into Phase 2 clinical evaluation

No dose-limiting toxicities were reported. The pharmacokinetic data confirmed that targeted exposures of danegaptide were reached as guided by preclinical data. Early signs of clinical activity were observed on retinal imaging, with reductions in retinal vascular leakage and improvements in anatomic parameters observed.

“An oral approach like danegaptide has the potential to fundamentally shift how we treat moderate-to-severe stages of diabetic eye disease, offering patients a much-needed and non-invasive treatment solution for the large group of patients with NPDR,” said Carl Regillo, MD, Director of Retina Service of Wills Eye Hospital, Professor of Ophthalmology at Thomas Jefferson University in Philadelphia, and a member of the Breye Therapeutics Scientific Advisory Board.

“These results continue to support danegaptide’s potential as an oral, non-invasive therapeutic solution for patients in the earlier stages of diabetic retinopathy. As we now prepare to advance into Phase 2 clinical evaluation, our focus is on validating these findings using regulatory-accepted clinical outcomes to progress our mission of developing safe and effective treatment options for these patients to preserve their vision before the onset of irreversible damage. Additionally, we believe this treatment solution may also support the maintenance of treatment response after induction therapy with intravitreally administered products,” according to Ulrik Mouritzen, Chief Executive Officer of Breye Therapeutics.

A subsequent Phase 2 trial is planned to evaluate danegaptide in a targeted NPDR patient population using the regulatory endpoint of ≥2-step improvement on the Diabetic Retinopathy Severity Scale.

Reference

1. Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy. Breye Therapeutics. Press release. Published June 24, 2025. Accessed June 25, 2025. https://www.prnewswire.com/news-releases/breye-therapeutics-announces-successful-completion-of-its-phase-1b-trial-with-danegaptide-in-patients-with-diabetic-retinopathy-302488402.html

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
© 2025 MJH Life Sciences

All rights reserved.